Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.32 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | NOS2 | P35228 | 2/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3025621 | 0.93 | PRMT6 (0.30) | NOS3NOS1NOS2 | |
| SCHEMBL3021993 | 0.93 | HCRTR2 (0.33) | HCRTR2NOS3NOS1NOS2DYRK1A | |
| SCHEMBL3022781 | 0.93 | HCRTR2 (0.33) | HCRTR2NOS3NOS1NOS2DYRK1A | |
| SCHEMBL3695591 | 0.85 | CTSL (0.35) | NOS3NOS1NOS2DYRK1ABACE1 | |
| SCHEMBL3029229 | 0.84 | GRIN2B (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL3021991 | 0.84 | GRIN2B (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL3025257 | 0.77 | CTSL (0.32) | HCRTR2NOS3NOS1NOS2DYRK1A | |
| SCHEMBL3025253 | 0.77 | CTSL (0.32) | HCRTR2NOS3NOS1NOS2DYRK1A | |
| SCHEMBL3030050 | 0.76 | NPC1 (0.38) | — | |
| SCHEMBL3030053 | 0.76 | NPC1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190829-B1 | AMIDINE, THIOUREA AND GUANIDINE DERIVATIVES OF 2-AMINOBENZOTHIAZOLES AND AMINOBENZOTHIAZINES FOR THEIR USE AS PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGIES | Rottapharm Biotech Srl (IT) | 2016-08-17 | — | — | EP | claimed |
| EP-2190829-B1 | AMIDINE, THIOUREA AND GUANIDINE DERIVATIVES OF 2-AMINOBENZOTHIAZOLES AND AMINOBENZOTHIAZINES FOR THEIR USE AS PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGIES | Rottapharm Biotech Srl (IT) | 2016-08-17 | — | — | EP | disclosed |
| US-8420634-B2 | Amidine, thiourea and guanidine derivatives of 2-aminobenzothiazoles and aminobenzothiazines for their use as pharmacological agents for the treatment of neurodegenerative pathologies | ROTTAPHARM S.P.A. (IT) | 2013-04-16 | — | — | US | disclosed |
| US-20100197670-A1 | AMIDINE, THIOUREA AND GUANIDINE DERIVATIVES OF 2-AMINOBENZOTHIAZOLES AND AMINOBENZOTHIAZINES FOR THEIR USE AS PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGIES | ROTTAPHARM BIOTECH S.R.L. (IT) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197670-A1 | AMIDINE, THIOUREA AND GUANIDINE DERIVATIVES OF 2-AMINOBENZOTHIAZOLES AND AMINOBENZOTHIAZINES FOR THEIR USE AS PHARMACOLOGICAL AGENTS FOR THE TREATMENT OF NEURODEGENERATIVE PATHOLOGIES | ABAT, SMN1; SMN2, IAPP | HCRTR2 2632/4885NOS3 204/4885NOS1 241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.